初始接种两剂灭活疫苗的成人接种一剂单价BNT162b2加强针后抗体应答持续12个月
本研究纳入277名初始接种两剂灭活疫苗后接受第三剂异源BNT162b2疫苗的成人,观察抗体应答强度和持久性。针对原始株和Omicron BA.2亚型的 neutralizing antibody 水平从第三剂后1个月至6个月下降,随后维持至12个月。第三剂后365天,同时接种第四剂且报告SARS-CoV-2感染者抗体滴度最高;有慢性基础疾病者针对Omicron BA.2亚型的抗体水平在第三剂后12个月较低。
要点
- 第三剂异源BNT162b2后中和抗体从1个月至6个月下降,维持至12个月。
- 第三剂后365天,接种第四剂且报告感染者抗体滴度最高。
- 有慢性基础疾病者第三剂后12个月针对Omicron BA.2抗体较低。
核心结论
- 异源第三剂BNT162b2可提供持久的中和抗体应答,可能受后续感染或疫苗接种及既往基础疾病影响。
- 这些发现可能有助于解释疫苗接种与自然感染之间免疫保护的差异。
研究设计与样本
- 研究纳入277名初始接种两剂灭活疫苗后接受第三剂异源BNT162b2疫苗的成人,观察抗体应答强度和持久性。
主要发现
- 针对原始株和Omicron BA.2亚型的中和抗体水平从第三剂后1个月至6个月下降,随后维持至12个月。
- 第三剂后365天,同时接种第四剂且报告SARS-CoV-2感染者抗体滴度最高。
- 有慢性基础疾病者第三剂后12个月针对Omicron BA.2亚型的抗体水平较低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study examined the strength and durability of antibody responses in 277 adults who received a heterologous third dose of the BNT162b2 vaccine, following two doses of an inactivated vaccine. Neutralizing antibody levels against both the ancestral virus and Omicron BA.2 subvariant decreased from one month to 6 months after the third dose, and were then maintained at 12 months. Participants who received both a fourth dose and reported a SARS-CoV-2 infection had the highest antibody titers at 365 days after the third dose. Individuals with chronic medical conditions had lower antibody levels against the Omicron BA.2 subvariant at 12 months after the third dose. The results suggest that the heterologous third dose provides durable neutralizing antibody responses, which may be influenced by subsequent infection or vaccination and pre-existing medical conditions. These findings may help explain the differences in immune protection between vaccination and natural infection.
引用
- Shiu EYC, Cheng SMS, Martín-Sánchez M, et al. Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine. Vaccine. 2024. PMID: 39276621. doi:10.1016/j.vaccine.2024.126317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。